Share on StockTwits
 

Canaccord Genuity boosted their price objective on shares of InterMune (NASDAQ:ITMN) from $17.00 to $22.00 in a research note issued on Tuesday, Stock Ratings News reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s target price points to a potential upside of 24.58% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Stifel Nicolaus raised their price target on shares of InterMune from $20.00 to $23.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at UBS AG raised their price target on shares of InterMune from $15.00 to $19.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $18.63.

InterMune (NASDAQ:ITMN) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.61) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.71) by $0.10. The company had revenue of $19.72 million for the quarter, compared to the consensus estimate of $16.44 million. During the same quarter in the prior year, the company posted ($0.63) earnings per share. The company’s quarterly revenue was up 161.9% on a year-over-year basis.

In other InterMune news, CEO Daniel G. Welch unloaded 50,000 shares of InterMune stock on the open market in a transaction dated Friday, January 10th. The stock was sold at an average price of $17.00, for a total value of $850,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.